Sui Xinbing, Guo Yong, Ni Wei, Jin Haiyan, Lin Haoming, Xie Tian
Department of Medical Oncology, Holistic Integrative Oncology Institutes and Holistic Integrative Cancer Center of Traditional Chinese and Western Medicine, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Department of Cancer Pharmacology, Holistic Integrative Pharmacy Institutes, College of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Integr Med Res. 2019 Mar;8(1):21-25. doi: 10.1016/j.imr.2018.11.001. Epub 2018 Nov 24.
Traditional Chinese medicine (TCM) syndromes ( in Chinese) constitute the basis of understanding the disorders of patients and guiding the use of the Chinese herbs. Colorectal cancer is divided into various subtypes mainly according to the identification.
We aimed to determine the molecular basis underlying - (spleen deficiency) and - (dampness-heat) that are commonly found in colorectal cancer patients.
About 80 colorectal cancer patients, including 47 - and 33 - were enrolled. Blood and tissue samples of these patients were available for protein and mRNA expression. The protein expression was determined by Immunohistochemistry (IHC) staining and mRNA profiling was detected by expression microarray. Furthermore, mRNA fold change was evaluated by qRT-PCR.
The colorectal cancer patients with - had a poor prognosis, compared with - (95% CI: 0.05-0.33; < 0.0001). Moreover, there was a significant difference in protein expression levels (especially for mutant TP53, PCNA, PD-L1 and Ki-67) among - and - ( < 0.01). Meanwhile, mRNA expression (especially for wild type TP53, KDM6A, PCNA, PD-L1, Ki-67, CCL-2, IL-1a and COX-2) was also remarkably different between - and - groups ( < 0.01).
Our results suggest that - conditions may contribute to poor overall survival in patients with colorectal cancer. Compared with -, high expression of mutant TP53, PCNA, PD-L1, Ki-67, CCL-2, IL-1a and COX-2 may serve as potential biomarkers for diagnosis and prognosis of colorectal cancer patients displayed -.
中医证候是理解患者疾病和指导中药使用的基础。结直肠癌主要根据辨证分为多种亚型。
我们旨在确定结直肠癌患者中常见的（脾虚）和（湿热）证型的分子基础。
纳入约80例结直肠癌患者，其中47例为（脾虚）证型，33例为（湿热）证型。这些患者的血液和组织样本可用于蛋白质和mRNA表达检测。蛋白质表达通过免疫组织化学（IHC）染色测定，mRNA谱通过表达微阵列检测。此外，通过qRT-PCR评估mRNA的倍数变化。
与（湿热）证型相比，（脾虚）证型的结直肠癌患者预后较差（95%可信区间：0.05 - 0.33；P < 0.0001）。此外，（脾虚）证型和（湿热）证型之间的蛋白质表达水平（特别是突变型TP53、PCNA、PD-L1和Ki-67）存在显著差异（P < 0.01）。同时，（脾虚）证型和（湿热）证型组之间的mRNA表达（特别是野生型TP53、KDM6A、PCNA、PD-L1、Ki-67、CCL-2、IL-1α和COX-2）也有显著差异（P < 0.01）。
我们的结果表明，（脾虚）证型可能导致结直肠癌患者总体生存率较差。与（湿热）证型相比，突变型TP53、PCNA、PD-L1、Ki-67、CCL-2、IL-1α和COX-2的高表达可能作为显示（脾虚）证型的结直肠癌患者诊断和预后的潜在生物标志物。
